Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P32241
UPID:
VIPR1_HUMAN
Alternative names:
Pituitary adenylate cyclase-activating polypeptide type II receptor; VPAC1
Alternative UPACC:
P32241; A5JUT9; B3KPV1; B4DEB5; B4DGI4; F5H1F5; G3V0I1; Q15871; Q6P2M6
Background:
Vasoactive intestinal polypeptide receptor 1 (VIPR1), also known as VPAC1, is a critical receptor that binds vasoactive intestinal polypeptide (VIP) with high affinity. Its activity is mediated through G proteins that activate adenylyl cyclase, leading to increased levels of cyclic AMP. VIPR1 shows a preference for VIP over pituitary adenylate cyclase-activating polypeptide (PACAP-27 and PACAP-38), highlighting its specificity in cellular signaling pathways.
Therapeutic significance:
Understanding the role of Vasoactive intestinal polypeptide receptor 1 could open doors to potential therapeutic strategies. Its involvement in cyclic AMP signaling pathways suggests its potential impact on diseases where these pathways are dysregulated. Exploring VIPR1's functions and interactions could lead to novel treatments for such conditions.